EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide

Hany Elmariah, Salman Otoukesh, Ambuj Kumar, Haris Ali, Shukaib Arslan, Elizabeth Dimaggio, Rebecca Gonzalez, Geoffrey Shouse, Hoda Pourhassan, Taiga Nishihori, Rawan Faramand, Asmita Mishra und 13 weitere

Transplantation and Cellular Therapy · 2024

DOI: 10.1016/j.jtct.2024.07.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation and Cellular Therapy, 2024. Verfasst von Hany Elmariah und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Hauptthemen laut MEDLINE: Mycophenolic Acid, Cyclophosphamide, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycophenolate mofetil (MMF) is commonly included in post-transplant cyclophosphamide (PTCy) based graft-versus-host disease (GVHD) prophylaxis after haploidentical (haplo) hematopoietic cell transplant (HCT). In the non-PTCy setting, higher MMF dose/kg has been shown to reduce rates of acute graft-versus-host disease (GVHD). When used in conjunction with PTCy, MMF is dosed at 15 mg/kg three times daily up to a maximum dose of 3 g/day. Thus, patients who weigh ≥67 kg receive 3 g/day and a variable dose/kg of MMF. We investigated the impact of MMF dose/kg on clinical outcomes following haploidentical PBSCT with PTCy-based GVHD prophylaxis. All consecutive adult patients with hematologic malignancies receiving haploidentical T cell replete peripheral blood stem cell transplant (PBSCT) with PTCy/MMF and either tacrolimus or sirolimus at the Moffitt Cancer Center or City of Hope between April 2014-August 2020 were included. For analyses, MMF dose relative to patient actual body weight (mg/kg/day), was stratified into categories of low ( 41 mg/kg/day). Three hundred eighty-six patients were included. Of these, 54 patients received low dose, 73 low intermediate, 137 high intermediate and 122 high dose MMF by relative weight exposure. In multivariate analysis, low MMF dose exposure was associated with reduced rates of relapse in comparison to the high dose group (HR = 0.45, 95% CI: 0.21 to 0.94, P = .03). This led to superior PFS among patients with low compared to high MMF dose exposure (HR = 0.58, 95% CI: 0.34 to 0.99, P = .045). MMF relative dose exposure was not associated with engraftment, GVHD, nonrelapse mortality, or OS. In this study of patients receiving haploidentical PBSCT with PTCy based GVHD prophylaxis, low MMF dose/kg was associated with improved rates of relapse and PFS. Future prospective studies should investigate optimal dosing strategies of MMF when given with the PTCy regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycophenolic AcidCyclophosphamideHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansMaleFemaleMiddle AgedAdultTransplantation, HaploidenticalBody WeightImmunosuppressive AgentsHematologic NeoplasmsTreatment OutcomeAgedTacrolimusYoung Adult

Stichwörter der Autor:innen

GVHDHaploidenticalMMFMycophenolate mofetilPost-transplant cyclophosphamide

Substanzen

Mycophenolic AcidCyclophosphamideImmunosuppressive AgentsTacrolimus

Autor:innen und Institutionen

  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
  • Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California.
  • University of South Florida, Tampa, Florida.
  • Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. Electronic address: Nelli.Bejanyan@moffitt.org.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

Elmariah, H., Otoukesh, S., Kumar, A., Haris Ali, Shukaib Arslan, Dimaggio, E., Gonzalez, R., Shouse, G., Pourhassan, H., Taiga Nishihori, Faramand, R., Mishra, A., Khimani, F., Fernandez, H., Lazaryan, A., Nieder, M., Perez, L., Liu, H., Ryotaro Nakamura, …, & Monzr M Al Malki (2024). Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide. Transplantation and Cellular Therapy. https://doi.org/10.1016/j.jtct.2024.07.024

Vancouver

Elmariah H, Otoukesh S, Kumar A, Haris Ali, Shukaib Arslan, Dimaggio E, et al. Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide. Transplantation and Cellular Therapy. 2024. doi:10.1016/j.jtct.2024.07.024

BibTeX
@article{Elmariah2024,
  author = {Elmariah, Hany and Otoukesh, Salman and Kumar, Ambuj and Haris Ali and Shukaib Arslan and Dimaggio, Elizabeth and Gonzalez, Rebecca and Shouse, Geoffrey and Pourhassan, Hoda and Taiga Nishihori and Faramand, Rawan and Mishra, Asmita and Khimani, Farhad and Fernandez, Hugo and Lazaryan, Aleksandr and Nieder, Michael and Perez, Lia and Liu, Hien and Ryotaro Nakamura and Pidala, Joseph and Guido Marcucci and Stephen J Forman and Anasetti, Claudio and Bejanyan, Nelli and Monzr M Al Malki},
  title = {Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide},
  journal = {Transplantation and Cellular Therapy},
  year = {2024},
  doi = {10.1016/j.jtct.2024.07.024}
}
Kostenlos starten →